CELLDEX THERAPEUTICS INC NEW's ticker is CLDXXXXX and the CUSIP is 15117B103. A total of 134 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q4 2017. The put-call ratio across all filers is 1.00 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2018 | $9,000 | +12.5% | 45,687 | +154.4% | 0.00% | 0.0% |
| Q3 2018 | $8,000 | +700.0% | 17,958 | +6478.0% | 0.00% | – |
| Q4 2017 | $1,000 | -98.1% | 273 | -98.5% | 0.00% | -100.0% |
| Q3 2017 | $52,000 | +5100.0% | 18,014 | +3517.3% | 0.00% | – |
| Q2 2017 | $1,000 | -97.7% | 498 | -95.9% | 0.00% | -100.0% |
| Q4 2016 | $44,000 | +780.0% | 12,196 | +908.8% | 0.01% | – |
| Q3 2016 | $5,000 | – | 1,209 | +1214.1% | 0.00% | – |
| Q1 2016 | $0 | -100.0% | 92 | -85.0% | 0.00% | -100.0% |
| Q4 2015 | $10,000 | -85.7% | 612 | -78.0% | 0.00% | -66.7% |
| Q2 2015 | $70,000 | +89.2% | 2,787 | +112.4% | 0.01% | +20.0% |
| Q1 2015 | $37,000 | -32.7% | 1,312 | -58.0% | 0.01% | -28.6% |
| Q1 2014 | $55,000 | +3.8% | 3,122 | +43.7% | 0.01% | -22.2% |
| Q4 2013 | $53,000 | -79.1% | 2,172 | -69.7% | 0.01% | -66.7% |
| Q3 2013 | $254,000 | – | 7,169 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TSP Capital Management Group, LLC | 813,273 | $3,286,000 | 1.66% |
| RTW INVESTMENTS, LP | 1,243,164 | $5,022,000 | 1.52% |
| Marcus Capital, LLC | 112,200 | $453,000 | 0.44% |
| BOGLE INVESTMENT MANAGEMENT L P /DE/ | 996,178 | $4,024,000 | 0.29% |
| Benchmark Capital Advisors | 67,000 | $271,000 | 0.20% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 360,299 | $1,456,000 | 0.20% |
| COLUMBIA WANGER ASSET MANAGEMENT LLC | 2,907,523 | $11,746,000 | 0.15% |
| Virtus ETF Advisers LLC | 59,537 | $241,000 | 0.12% |
| Bellevue Group AG | 160,000 | $646,000 | 0.12% |
| PDT Partners, LLC | 428,300 | $1,730,000 | 0.10% |